NICE refuses the appeal for Alzheimer's drug treatments

NICE has today (Wednesday 11 October) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer's disease have not been upheld.

Test for Alzheimer's disease
Test for Alzheimer's disease

This final guidance from NICE will recommend to the NHS in November that donepezil, galantamine and rivastigmine should only be considered as options for treatment of people with moderate Alzheimer’s disease. Memantine is only recommended as part of clinical studies for people with moderate-severe to severe Alzheimer’s disease.

In 2001 NICE guidance recommended that the Alzheimer’s drugs should be used as a standard treatment. However, a further appraisal in 2005 resulted in NICE stating that the drugs should be restricted as the cost of treating these patients was not supported by the available evidence.

The pharmaceutical manufacturers were asked to present further evidence of the effectiveness of these treatments in patients with mild Alzheimer’s disease.

Andrew Dillon, NICE chief executive, said: ‘Alzheimer’s is a cruel and devastating illness and we realise that today’s announcement will be disappointing to people with Alzheimer’s disease and those who treat and care for them. But we have to be honest and say that based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough difference for us to recommend their use for treating all stages of Alzheimer’s disease.’

Pfizer and Eisai, manufacturers of donepezil, are reported to be considering a judicial review of the decision.


eMIMS links

Alzheimer's dementia

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

The healthcare crisis in Myanmar - how UK GPs can help

The healthcare crisis in Myanmar - how UK GPs can help

Dr Jim Brockbank from Myanmar UK GP Health Action provides an update on how the military...

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

More than four fifths of GPs say e-consultation systems adopted in the pandemic have...

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Tens of millions of COVID-19 jabs have been administered across England, but how...

Podcast: Greener practice, sharing patient data and additional roles

Podcast: Greener practice, sharing patient data and additional roles

In this episode we look at data extraction from GP records, ask whether the additional...

Red flag symptoms: Loss of consciousness

Red flag symptoms: Loss of consciousness

Red flag symptoms to look out for in presentations of loss of consciousness, including...

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

NHS England has announced £20m in funding to help local COVID-19 vaccination sites...